CLINICAL TRIALS PROFILE FOR NEO-MEDROL

All Clinical Trials for Neo-medrol

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗	Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 2	1993-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002831 ↗	Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	1995-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.
NCT00002831 ↗	Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia	Completed	M.D. Anderson Cancer Center	Phase 1/Phase 2	1995-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of high-dose chemotherapy plus peripheral stem cell transplantation in treating patients with chronic myelogenous or acute leukemia.

Clinical Trial Conditions for Neo-medrol

Condition Name

Condition Name for Neo-medrol
Intervention	Trials
Leukemia	15
Acute Lymphoblastic Leukemia	6
Osteoarthrosis	6
Graft Versus Host Disease	6

Condition MeSH

Condition MeSH for Neo-medrol
Intervention	Trials
Leukemia	22
Leukemia, Lymphoid	16
Precursor Cell Lymphoblastic Leukemia-Lymphoma	15
Syndrome	13

Clinical Trial Locations for Neo-medrol

Trials by Country

Trials by Country for Neo-medrol
Location	Trials
United States	425
Canada	42
China	16
Denmark	14
Australia	12

Trials by US State

Trials by US State for Neo-medrol
Location	Trials
Texas	30
California	21
Ohio	17
Georgia	16
New York	16

Clinical Trial Progress for Neo-medrol

Clinical Trial Phase

Clinical Trial Phase for Neo-medrol
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	1
PHASE2	2

Clinical Trial Status

Clinical Trial Status for Neo-medrol
Clinical Trial Phase	Trials
Completed	58
Recruiting	20
Active, not recruiting	12

Clinical Trial Sponsors for Neo-medrol

Sponsor Name

Sponsor Name for Neo-medrol
Sponsor	Trials
National Cancer Institute (NCI)	20
M.D. Anderson Cancer Center	16
Rigshospitalet, Denmark	7

Sponsor Type

Sponsor Type for Neo-medrol
Sponsor	Trials
Other	139
Industry	40
NIH	32

Last updated: April 28, 2026

Neo-medrol: What the clinical-trial and market-projection picture shows

Is Neo-medrol in active clinical development?

No complete, verifiable public record of a drug product named “Neo-medrol” tied to (1) a unique INN/USAN/generic name, (2) sponsor, and (3) identifiable clinical study identifiers (e.g., NCT/EudraCT) is available in the provided context. Without that mapping, an accurate clinical-trials update cannot be produced.

What market segment does Neo-medrol target, and what are the demand drivers?

“Neo-medrol” is not identifiable from the provided context as a specific, legally-defined drug entity with an established therapeutic indication, dosage form, strength, route, or claim set. Those elements are required to produce a market analysis by indication, geography, and payer setting.

Can a market projection be produced for Neo-medrol?

A defensible market projection requires at minimum:

• the active ingredient and therapeutic class (and whether it is a new molecular entity, new combination, new formulation, or a repurposed use)
• the indication(s) under study/approved
• geography and channel assumptions (hospital vs retail, reimbursed vs OTC, tender-driven vs private)
• competitive set (originator vs generics vs branded competitors) and key differentiators tied to measurable outcomes

No such inputs are present in the provided context. A projection would therefore not be reliably anchored to actual product data.

---

What would an investor-grade update require, and why it cannot be completed here

A “clinical trials update, market analysis and projection” is only actionable when it is built from auditable inputs: trial IDs, endpoints, enrollment status, and regulatory milestones; plus market sizing methods that map to the drug’s actual indication and competitive environment.

In the absence of an identifiable “Neo-medrol” drug definition, any attempt to populate those sections would require speculation on:

• therapeutic indication and mechanism
• trial design (phase, comparator, endpoints)
• recruitment and completion dates
• jurisdictional regulatory status
• pricing and reimbursement path
• competing products and market share capture

Under the constraints here, that level of guesswork cannot be translated into a complete and accurate report.

---

Key Takeaways

• A precise clinical-trials update for “Neo-medrol” cannot be produced without an unambiguous identification of the drug entity and its public study identifiers.
• A market analysis and projection cannot be produced without the active ingredient/class and the indication-level commercial scope.
• Any numerical projections, competitor mapping, or regulatory timelines would be speculative without verifiable anchors.

---

FAQs

1) What clinical-trials dataset should be used for Neo-medrol updates?

A credible update uses public trial registries (e.g., ClinicalTrials.gov and EU Clinical Trials Register) with NCT/EudraCT identifiers matched to the exact drug entity.

2) What market method fits a mid-stage or near-approval drug?

Industry-standard approaches map forecast demand by indication, penetration path (coverage and formulary placement), and competitive set using product-level assumptions.

3) Does “Neo-medrol” imply a corticosteroid product?

The name alone is not sufficient to confirm active ingredient, formulation, or indication.

4) How are clinical endpoints linked to market forecasting?

Endpoints translate into payer and provider adoption levers via efficacy, safety, and comparative advantage versus current standards of care.

5) What proof points drive valuation in this category?

Phase completion, readouts with statistically and clinically meaningful endpoints, and clear regulatory milestones tied to label scope.

---

References

[1] ClinicalTrials.gov. (n.d.). Study record database. https://clinicaltrials.gov/
[2] European Union Clinical Trials Register. (n.d.). EudraCT database. https://www.clinicaltrialsregister.eu/